Literature DB >> 7540003

Evidence against dephosphorylation of insulin-elicited phosphotyrosine proteins in vivo by the phosphatase PTP2C.

M R Kuhné1, Z Zhao, G E Lienhard.   

Abstract

In order to determine whether the tyrosine phosphatase PTP2C dephosphorylates insulin-elicited phosphotyrosine proteins in vivo, we have compared the patterns of protein tyrosine phosphorylation and its reversal in the kidney 293 cell line with those in 293 cell lines overexpressing PTP2C and a catalytically inactive point mutant of PTP2C. In all three cell types insulin caused the rapid tyrosine phosphorylation of a 160 kD protein, which was shown not to be the insulin receptor substrate 1 (IRS-1) and may be the recently described IRS-2, as well as that of a 100 kD polypeptide, which is probably a mixture of the beta subunits of the insulin and insulin-like growth factor I receptors. There was no difference among the three cell lines in the extent of tyrosine phosphorylation or in the rate of its reversal upon insulin withdrawal. These results indicate that PTP2C does not function to dephosphorylate these proteins significantly in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540003     DOI: 10.1006/bbrc.1995.1795

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Altered basal and insulin-stimulated phosphotyrosine phosphatase (PTPase) activity in skeletal muscle from NIDDM patients compared with control subjects.

Authors:  D Worm; J Vinten; P Staehr; J E Henriksen; A Handberg; H Beck-Nielsen
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

2.  Focal adhesion kinase tyrosine phosphorylation is associated with myogenesis and modulated by insulin.

Authors:  H L Goel; C S Dey
Journal:  Cell Prolif       Date:  2002-06       Impact factor: 6.831

3.  IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation.

Authors:  Gerjon J Ikink; Mandy Boer; Elvira R M Bakker; John Hilkens
Journal:  Nat Commun       Date:  2016-11-23       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.